UPDATE: Canaccord Genuity Reiterates Buy Rating, Raises PT on NuVasive Following Q4/12 Results

In a report published Wednesday, Canaccord Genuity reiterated its Buy rating on NuVasive

, and raised its price target from $22.50 to $25.00. Canaccord Genuity noted, “We note strength across all key business units in Q4/12 including XLIF, both US and OUS, and biologics is encouraging, capping off a lumpy 2012. Additionally, 2013 appears to be a year of major initiatives as the company anticipates major growth in Japan as well as multiple new product launches into the US markets.” NuVasive closed on Tuesday at $18.42.